SCHEMBL17757151

SCHEMBL17757151

c1ccc(CNC2=Nc3ncccc3NC23CCCCC3)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 1/20 0.38
▸ FABP1 P07148 1/20 0.38
▸ FABP6 P51161 1/20 0.38
▸ BACE1 P56817 1/20 0.37
▸ ACAT2 Q9BWD1 1/20 0.36
▸ CXCR4 P61073 1/20 0.35
▸ ACHE P22303 2/20 0.35
▸ TSHR P16473 1/20 0.35
▸ EGFR P00533 2/20 0.34
▸ NOS2 P35228 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ASPH Q12797 1/20 0.34
▸ KDM8 Q8N371 1/20 0.34
▸ CDC7 O00311 2/20 0.33
▸ AKT1 P31749 2/20 0.33
▸ PLK4 O00444 1/20 0.33
▸ CHEK1 O14757 1/20 0.33
▸ JAK2 O60674 1/20 0.33
▸ ROCK2 O75116 1/20 0.33
▸ INSR P06213 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17755497 0.87 GRM4 (0.43) ACAT2EGFRCDC7KDRCCNT1
SCHEMBL17757241 0.85 ALDH1A1 (0.40) AKT1CHEK1ROCK2PIM1PRKACA
SCHEMBL17757155 0.85 KMT2A (0.37) KMT2AFABP1FABP6ACAT2ACHE
SCHEMBL21982596 0.84 KMT2A (0.39) KMT2AFABP1FABP6BACE1CXCR4
SCHEMBL17757153 0.84 CYP1A2 (0.37) KMT2ATSHREGFRKDM4EAKT1
SCHEMBL17757467 0.83 KMT2A (0.41) KMT2AACAT2ACHETSHRKDM4E
SCHEMBL14398518 0.83 KMT2A (0.41) KMT2AACAT2ACHETSHRKDM4E
SCHEMBL17757653 0.83 KMT2A (0.41) KMT2AACAT2ACHETSHRKDM4E
SCHEMBL17757634 0.81 KMT2A (0.39) KMT2AFABP1FABP6ACAT2ACHE
SCHEMBL17757150 0.81 KMT2A (0.38) KMT2AFABP1FABP6BACE1ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-05-12 — — US disclosed
WO-2016075137-A1 SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2016-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 KMT2A 4518/4885FABP1 1158/4885FABP6 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback